LIXT vs. ASLN, BFRI, TFFP, BNOX, UPC, CMMB, KTTA, KA, HEPA, and CYCN
Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include ASLAN Pharmaceuticals (ASLN), Biofrontera (BFRI), TFF Pharmaceuticals (TFFP), Bionomics (BNOX), Universe Pharmaceuticals (UPC), Chemomab Therapeutics (CMMB), Pasithea Therapeutics (KTTA), Kineta (KA), Hepion Pharmaceuticals (HEPA), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical preparations" industry.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
ASLAN Pharmaceuticals' return on equity of -1,202.60% beat Lixte Biotechnology's return on equity.
58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 15.5% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
ASLAN Pharmaceuticals has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500.
ASLAN Pharmaceuticals currently has a consensus target price of $11.33, suggesting a potential upside of 2,379.40%. Given Lixte Biotechnology's higher possible upside, equities research analysts clearly believe ASLAN Pharmaceuticals is more favorable than Lixte Biotechnology.
Lixte Biotechnology has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Lixte Biotechnology is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, ASLAN Pharmaceuticals had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 2 mentions for ASLAN Pharmaceuticals and 1 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.06 beat ASLAN Pharmaceuticals' score of -0.50 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the media.
ASLAN Pharmaceuticals received 199 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
Summary
ASLAN Pharmaceuticals beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks.
Get Lixte Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lixte Biotechnology Competitors List
Related Companies and Tools
